Sorted By:


Power of Medicines: Saving Lives and Building the Future

PhRMA  |  Video

Not long ago HIV was an acute, fatal illness. Today, thanks in part to innovative medicines, the U.S. death rate for HIV/AIDS has fallen nearly 85 percent since its peak, and is now considered by many to be a manageable chronic disease. Therapeutic advances have also transformed treatment of rheu...

Medicare Monday: A discussion on affordability and access to medicines

PhRMA  |  Blog Post

“Older adults with diabetes who were adherent to their medicines saved an average of $5,170 per year compared to non-adherent beneficiaries, according to Roebuck in the .org/WorkArea/DownloadAsset.aspx?

Medicare Monday: 10 years later, 3 reasons why Part D is a success story

PhRMA  |  Blog Post

January 2016 marks the 10th anniversary of the implementation of Medicare Part D. Medicare’s prescription...

FDA Modernization

PhRMA  |  From PhRMA


Panel Discussion and New Report Highlight Benefit of Vermont Clinical Trials for Patients, State Economy

PhRMA  |  Press Release

"New medicines are only possible through collaboration, and Vermont demonstrates the power of public-private partnerships to elevate science and bring medicines to patients.

I'm Not Average: 13 Years Later, Jamie Is Still Here

PhRMA  |  Blog Post

Jamie Pires fainted in her doctor’s office when she was told she has Chronic Myelogenous Leukemia (CML), a cancer the starts inside the bone marrow. This wasn’t supposed to happen. Even her doctor thought she was in good health. ...

Follow the Dollar Report

PhRMA  |  Report

This paper provides a high-level explanation of the financial flows that occur as brand medicines move through the supply chain for retail, mail-order, and specialty drugs.

PhRMA & BIO release joint principles on communications with health care professionals and payers

PhRMA  |  Blog Post

Learn more about communications with health care professionals and payers here.

New Study Examines Clinical Pathways: An Overview of Current Practices and Potential Implications for Patients, Payers, and Providers

PhRMA  |  Blog Post

A recent paper by the Personalized Medicine Coalition notes: “As personalized medicine provides new insights on the role of genetic variation in what works or does not work for a patient, clinical pathways and other decision support tools will be challenged to keep pace with changes in evidence – and importantly, what works for an individual patient.

Questions and Answers for Peer Speakers Program for Health Care Professionals

PhRMA  |  Report

Compensation for this time is, per the PhRMA Code, to be reasonable and at fair-market value for the services provided.

Principles On Responsible Sharing of Truthful and Non-Misleading Information About Medicines with Health Care Professionals and Payers

PhRMA  |  Codes & Guidelines

These principles are intended to form the basis for defining new and clear regulatory standards governing responsible, truthful and non-misleading communications to inform health care professionals and payers about the safe and effective use of medicines.

The journey to better health care requires a holistic view

PhRMA  |  Blog Post

Understanding the cost constraints that confront both private and public payers, policy approaches targeting medicines’ budgets in isolation for the sake of short-term savings are not the right response.

A Delicate Balance - Pharmaceutical Innovation and Access

PhRMA  |  Codes & Guidelines

By William W. Chin, M.D. Chief Medical Officer and Executive Vice President, Science and Regulatory Affairs, PhRMA published in The New England Journal of Medicine....

Director – Federal Advocacy

PhRMA  |  PhRMA Career

We are committed to supporting our family of professionals at PhRMA and strive to create programs that help our team members manage the challenges of balancing a fast-paced career with their own personal goals.

Testimony of Lori M. Reilly Before the Senate Health, Education, Labor and Pensions Committee

PhRMA  |  Speeches & Communication

Reilly, executive vice president, policy, research, and membership at PhRMA, before the Senate Health, Education, Labor and Pensions Committee on October 17, 2017.

Excerpts from testimony by PhRMA’s Lori Reilly

PhRMA  |  Blog Post

Market-Based Approaches Are the Best Solution for Addressing Health Care Affordability and Controlling Costs These include encouraging payers to share negotiated savings with patients at the pharmacy counter; reforming outdated regulations hindering the adoption of value based payment arrangements, reforming the 340B drug discount program to better serve the purpose for which it was created; and continuing to modernize the FDA and ensure robust generic and biosimilar competition.

A New Era in Cancer Innovation

PhRMA  |  Video

Elizabeth Jaffee of Johns Hopkins, Sean Parker of the Parker Institute for Cancer Immunotherapy and Mark Alles, CEO at Celgene Corporation on the new era in cancer innovation.

Modernizing Drug Discovery, Development & Approval

PhRMA  |  Report

Developing an innovative medicine is a lengthy and complex process, taking an average of 10 or more years. The clinical trial component alone takes roughly six to seven years. With just 12 percent of drugs that enter clinical trials resulting in an approved medicine, the average research and deve...


PhRMA  |  From PhRMA

PhRMA hosts online and in-person events exploring science and policy issues that impact biopharmaceutical innovation and patient access to medicines.

Guest Post: Epilepsy Foundation on rare diseases

PhRMA  |  Blog Post

Some forms of epilepsy are rarer than others, but these rare syndromes can be the most catastrophic.

Innovation Spotlight: Battling Cancer Together

PhRMA  |  Video

Washington Ideas, hosted by The Atlantic, convened the nation's leading policy makers, journalists and thought leaders to discuss the most consequential issues facing the country.

The Biopharmaceutical Industry Invests More R&D Dollars per Employee Than Any Other Industry

Chartpack  |  From Our Network


Director – State Advocacy

PhRMA  |  PhRMA Career

Professional Experience / Requirements Bachelor’s degree in Public Policy, Health Policy, Political Science, Public Affairs, or related field (advanced degree preferred); 5-7 years of progressive experience in state government affairs and/or within state government/legislature/regulatory or executive branch; Working knowledge of state health care issues affecting the biopharmaceutical industry; Must be willing to travel (up to 50% of the time during certain times of the year) and be responsive and available after hours and on weekends as needed.

ICYMI: Survey highlights key barriers limiting number and scale of new approaches to paying for medicines

PhRMA  |  Blog Post

Allow a full range of truthful and non-misleading communications between innovators and payers for all medically accepted uses of medicines.

Medicare Monday: Catch up on MedPAC and its Part B recommendations

PhRMA  |  Blog Post

For policy wonks, you can get up to speed with our Memorial Day reading list on the Medicare Payment Advisory Commission (MedPAC), how it informs Medicare policy and its recent Part B recommendations, which are expected to be included in their report to Congress this June.

You have reviewed the first 125 results out of 1101. Each page contains 25 results. You're on page 5.

prev 1 2 3 4 5 6 next